



Antimicrobial Resistance: Epidemiology, Drivers, Dynamics, and Control

Guest Editor:

Prof. Dr. Ondřej Holý

Faculty of Health Sciences,
Palacký University Olomouc,
77515 Olomouc, Czech Republic

Deadline for manuscript
submissions:

closed (31 August 2022)

Message from the Guest Editor

Dear Colleagues,

Antimicrobial resistance (AMR) in bacterial pathogens is a worldwide challenge associated with high morbidity and mortality. In a global report on surveillance in AMR, The World Health Organization (WHO) declared that AMR in a wide range of infectious agents has become a serious public health problem and a post-antibiotic era is a real possibility in the 21st century. Although there are significant gaps in surveillance and a lack of standards for methodologies in many countries worldwide, the WHO reported very high rates of resistance both for health-care associated (HCA) and community-acquired (CA) infections. Fighting this threat is a public health priority that requires a collaborative global approach across sectors.

These resistant bacteria may infect humans and animals, and the infections they cause are harder to treat and are associated with higher medical costs, prolonged hospital stays, and increased morbidity, mortality and lethality.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi